TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

OVERVIEW OF ACTIVITY
Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year and account for more than one fourth of all newly diagnosed human cancer cases. Of this diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are thus the focus of extensive ongoing clinical research. A result of this research is that the clinical management of both early and more advanced presentations of prostate cancer (PC) is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians. To provide these clinicians with therapeutic strategies to address the needs of patients, this CME webinar originally planned as a live symposium for the 2020 ASCO Annual Meeting uses the perspectives of a group of leading clinical investigators to address some of the most frequently encountered questions and controversies in the management of PC. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of PC with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
• Appraise the similarities and differences among commercially available next-generation antiandrogens in order to personalize therapy selection for patients.
• Recognize the adverse effects associated with hormonal agents commonly employed in the management of PC, and develop strategies to prevent, mitigate and manage these toxicities.
• Explore available data on the use of cytotoxic and secondary hormonal therapy for hormone-sensitive metastatic PC in order to effectively design treatment plans for appropriate patients.
• Apply clinical research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic CRPC.
• Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.

COMPETENCIES TO BE ADDRESSED
Patient Care and Procedural Skills and Medical Knowledge

CONTACT INFORMATION
If you have questions regarding credit, please contact cpdsupport@usf.edu.

ACCREDITATION STATEMENT

CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelexis Inc, Pfizer Inc, Seattle Genetics.

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale University
New Haven, Connecticut

Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.

Christopher Sweeney, MBBS
Professor, Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme.

COURSE DIRECTOR/PANEL MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Pfizer Inc, Bayer HealthCare Pharmaceuticals, Exelixis Inc, and Sanofi Genzyme.

Release date: September 2020
Expiration date: September 2021